Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 201 - 241 av 241 resultater
Tid
Selskap
Tittel
Sektor
Kategori
21 Sep 2021
18:19 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
20103010 Biotechnology
Sales
21 Sep 2021
18:19 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics publie ses résultats semestriels et fait le point sur ses avancées
20103010 Biotechnology
Sales
20 Sep 2021
13:45 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
20103010 Biotechnology
Other subject
20 Sep 2021
13:45 CEST
OSE IMMUNOTHERAPEUTICS
Présentation des résultats positifs finaux pour Tedopi® dans l’essai clinique de Phase 3 chez des patients atteints de cancer du poumon non à petites cellules en résistance secondaire
20103010 Biotechnology
Other subject
20 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors
20103010 Biotechnology
Other subject
20 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics: Présentation à venir des résultats positifs pour Tedopi® dans l’essai clinique de Phase 3 chez des patients atteints de cancer du poumon non à petites cellules en résistance secondaire aux Checkpoint Inhibiteurs Immunitaires
20103010 Biotechnology
Other subject
16 Sep 2021
18:12 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics et Boehringer Ingelheim présentent des résultats de Phase 1 de BI 765063, inhibiteur first-in-class de SIRPα, dans les tumeurs solides avancées, au congrès de l’ESMO 2021
20103010 Biotechnology
Other subject
16 Sep 2021
18:12 CEST
OSE IMMUNOTHERAPEUTICS
Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
20103010 Biotechnology
Other subject
13 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
Boehringer Ingelheim et OSE Immunotherapeutics présentent des résultats positifs de Phase 1 de l’inhibiteur first-in-class de SIRPα BI 765063 dans les tumeurs solides avancées, au congrès de l’ESMO 2021
20103010 Biotechnology
Other subject
13 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
20103010 Biotechnology
Other subject
07 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics annonce l’accord de délivrance d’un nouveau brevet sur Tedopi® aux États-Unis
20103010 Biotechnology
Other subject
07 Sep 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
20103010 Biotechnology
Other subject
03 Sep 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
20103010 Biotechnology
Other subject
01 Sep 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
20103010 Biotechnology
Other subject
01 Sep 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
Présentation d’OSE Immunotherapeutics à la 23ème H.C. Wainwright Annual Global Investment Conference
20103010 Biotechnology
Other subject
26 Aug 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics et ARCAGY-GINECO annoncent la randomisation de la première patiente dans l’étude clinique de phase 2 évaluant Tedopi® en combinaison avec pembrolizumab dans le cancer de l’ovaire
20103010 Biotechnology
Other subject
26 Aug 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
20103010 Biotechnology
Other subject
25 Aug 2021
18:01 CEST
OSE IMMUNOTHERAPEUTICS
Servier et OSE Immunotherapeutics annoncent l’inclusion du premier patient dans l’essai clinique de phase 2 d’OSE-127/S95011 dans le syndrome de Sjögren
20103010 Biotechnology
Other subject
25 Aug 2021
18:01 CEST
OSE IMMUNOTHERAPEUTICS
Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
20103010 Biotechnology
Other subject
24 Aug 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics annonce ses prochains rendez-vous avec les investisseurs et son « R&D Day »
20103010 Biotechnology
Other subject
24 Aug 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
20103010 Biotechnology
Other subject
04 Aug 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
20103010 Biotechnology
Other subject
19 Jul 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics annonce la suspension volontaire des inclusions dans l’essai clinique de Phase 1 de CoVepiT
20103010 Biotechnology
Other subject
19 Jul 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
20103010 Biotechnology
Other subject
09 Jul 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
20103010 Biotechnology
Other subject
09 Jul 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics reçoit un versement de 10 millions d’euros au titre de la première tranche du prêt accordé par la Banque européenne d’investissement
20103010 Biotechnology
Other subject
07 Jul 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
20103010 Biotechnology
Other subject
30 Jun 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
20103010 Biotechnology
Other subject
30 Jun 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics signe un accord avec Cenexi pour la production de lots cliniques de CoVepiT, son vaccin multi-cibles de 2ème génération contre la COVID-19
20103010 Biotechnology
Other subject
24 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Résultats de l’Assemblée générale mixte à huis clos du 24 juin 2021
20103010 Biotechnology
General meeting / Board Meeting
24 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
20103010 Biotechnology
General meeting / Board Meeting
08 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital
20103010 Biotechnology
Other subject
03 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Assemblée générale mixte à huis clos le 24 juin 2021
20103010 Biotechnology
Other subject
03 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
20103010 Biotechnology
Other subject
02 Jun 2021
18:00 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics : Mise à disposition de l’amendement au Document d’Enregistrement Universel 2020
20103010 Biotechnology
Other subject
27 May 2021
18:08 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
20103010 Biotechnology
Other subject
27 May 2021
18:08 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics et la Fondation FoRT annoncent le démarrage d’une étude clinique de phase 2 évaluant Tedopi® en combinaison avec Opdivo® (nivolumab) dans le cancer du poumon non à petites cellules
20103010 Biotechnology
Other subject
26 May 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics annonce la première administration de son vaccin multi-variants de deuxième génération contre la COVID-19 chez un volontaire sain dans l’essai clinique de Phase 1
20103010 Biotechnology
Other subject
26 May 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
20103010 Biotechnology
Other subject
20 May 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
20103010 Biotechnology
Meetings / events
20 May 2021
07:30 CEST
OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics et Boehringer Ingelheim présentent des résultats positifs de Phase 1 de BI 765063, inhibiteur first-in-class de SIRPα, dans les tumeurs solides, au congrès de l’ASCO 2021
20103010 Biotechnology
Meetings / events
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva